Drug Combination Details
| General Information of the Combination (ID: C29596) | |||||
|---|---|---|---|---|---|
| Name | Sulforaphane NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Healthy individual
[ICD-11: N.A.]
|
Investigative | [1] | ||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Fibroblasts | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | GCLC | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | 4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | ||
| Experimental
Result(s) |
Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells. | |||||
| β. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | DNMT1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HDAC9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-10A | CVCL_0598 | Healthy | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| 13762 MAT B III | CVCL_3475 | Adenocarcinoma | Rattus norvegicus | |||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| NRCM | Healthy | Rattus norvegicus | ||||
| In-vivo Model | Non-tumor bearing female Sprague Dawley rats (age 6-8 weeks) were examined for the cardiac effects of SFN administration during chronic DOX treatment. | |||||
| Experimental
Result(s) |
Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. | |||||
| γ. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Fibroblasts | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Sulforaphane was able to reverse the resistance to doxorubicin. | |||||
